> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-07-21 06:08 KST **Entry ID:** 49 **Tags:** #marginal zone lymphoma #MZL #orelabrutinib #BTK inhibitor #BTKi #obinutuzumab #anti-CD20 #type-II glycoengineered mAb #refractory B-cell #non-Hodgkin lymphoma #spatial transcriptomics #tumor microenvironment --- ## 🔬 Today's Top Findings ### 1. Spatial transcriptomic rationale of orelabrutinib plus obinutuzumab in marginal zone lymphoma (GSE337521, score 6, n=3, Homo sapiens, spatial transcriptomics + clinical rationale, pdat 2026/07/15 = 6 days ago, the freshest BTK-inhibitor + anti-CD20 + refractory B-cell spatial dataset surfaced this cycle) ### 2. Humanized anti-Claudin-1 monoclonal antibody program for cholangiocarcinoma (GSE262166, score 6, n=77, Homo sapiens, mixed RNA-seq + clinical, pdat 2026/06/08, the largest-n refractory biliary-tract-cancer + tight-junction-target dataset in the scan and the only score-6 Claudin-1 therapeutic dataset) ### 3. Multiomics analyses of steroid drug efficacy in Duchenne muscular dystrophy cardiomyocytes (GSE312779, score 6, n=48, Homo sapiens, expression profiling, pdat 2026/05/05, the freshest DMD-cardiac-aging + steroid-efficacy multiomics dataset this cycle) ## 📋 Synthesis The 2026-07-21 06:00 KST research-watcher scan completed successfully with 105 hits across 27 queries. Three actionable signals survived the peptide / AI-infrastructure / longevity / cost screen, and all three are NOVEL versus yesterday's id:48 digest and absent from the retained id:43-id:48 window. (1) Refractory B-cell + spatial rationale: GSE337521 is a small-n (n=3) but freshly deposited spatial transcriptomic dataset paired with efficacy and safety data for orelabrutinib (a covalent BTK inhibitor) plus obinutuzumab (a glycoengineered type-II anti-CD20 monoclonal antibody) in marginal zone lymphoma. The deposit links a clinically actionable doublet to spatially resolved tumor microenvironment signal, which is exactly the kind of BTKi-resistance-and-CD20-cold-tumor evidence base that the Brown Biotech refractory B-cell lane needs. Caveat: n=3 limits any population-level claim \u2014 this is a high-value pilot, not a definitive atlas. (2) Refractory solid tumor + tight-junction target: GSE262166 (n=77) underwrites a humanized monoclonal antibody program against Claudin-1, a tight-junction protein that is overexpressed in cholangiocarcinoma and is otherwise pharmacologically inaccessible to standard-of-care gemcitabine/cisplatin/durvalumab. Claudin-1 sits at the intersection of ECM biology, tumor-stroma crosstalk, and biliary-tract oncology \u2014 three Brown Biotech lanes \u2014 and a n=77 humanized-mAb expression baseline is unusually large for a GEO therapeutic dataset. (3) Anti-aging / longevity + rare-disease muscle: GSE312779 (n=48) is a multiomics readout of steroid drug efficacy in DMD cardiomyocytes. DMD is the canonical accelerated-muscle-aging model, and steroid-responsiveness is the single biggest modifier of cardiac and skeletal-muscle function in these patients; a public n=48 expression dataset lets us benchmark steroid response signatures against the molecular-aging axis from yesterday's id:47 (exercise-trained human muscle) and earlier senescence atlases. Why this matters for Brown Biotech: together these three datasets define a reusable arc \u2014 spatial evidence for refractory B-cell targeted combinations, ECM/tight-junction target validation in biliary solid tumors, and steroid-efficacy benchmarking in DMD \u2014 that maps directly to the BB refractory-cancer + anti-aging lanes. None is a peptide-discovery hit, but all three are immediately actionable for the bioinformatics and target-validation services, and all three are first-time primary features today. --- ## 🎯 Highlights ### 1. Refractory B-cell + spatial rationale \u2014 GSE337521 (score 6, n=3 spatial samples; pdat 2026/07/15) deposits a freshly released spatial transcriptomic study paired with clinical efficacy and safety for orelabrutinib plus obinutuzumab in marginal zone lymphoma. Why it matters for BB: it is the freshest BTKi + anti-CD20 combination dataset with spatially resolved tumor-microenvironment signal in the scan and provides a direct evidence base for the BB refractory B-cell lane, including BTKi-resistance profiling and CD20-cold-tumor mapping. Caveat: n=3 is a pilot, not a population atlas \u2014 claims must be scoped accordingly. Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337521. GEO lists no PMID or DOI as of scan time. ### 2. Refractory solid tumor + tight-junction target \u2014 GSE262166 (score 6, n=77; pdat 2026/06/08) underwrites a humanized monoclonal antibody program targeting Claudin-1 in cholangiocarcinoma. The dataset combines expression profiling with clinical/translational annotation at n=77, which is unusually large for a GEO therapeutic entry. Why it matters for BB: cholangiocarcinoma remains one of the most refractory solid tumors (5-year survival <20%, limited targeted options beyond FGFR2 and IDH1), Claudin-1 is a tight-junction protein that is otherwise pharmacologically inaccessible to small molecules, and the ECM/biliary intersection maps directly to BB ECM and tumor-stroma services. Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE262166. GEO lists no PMID or DOI as of scan time. ### 3. Anti-aging / longevity + rare-disease muscle \u2014 GSE312779 (score 6, n=48; pdat 2026/05/05) is a multiomics study of steroid drug efficacy in DMD cardiomyocytes. Why it matters for BB: DMD is the canonical accelerated-muscle-aging model, steroid responsiveness is the single largest modifier of cardiac and skeletal-muscle function in DMD, and a public n=48 expression dataset lets us benchmark steroid-response signatures against molecular-aging axes from yesterday's id:47 (exercise-trained human muscle, GSE330697 n=93) and earlier senescence atlases. The dataset is actionable for the longevity and rare-disease lanes and complements the IPF/fibrosis emphasis of id:45-id:48 with a cardiac-and-skeletal-muscle viewpoint. Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312779. GEO lists no PMID or DOI as of scan time. ### 4. Four-axis decision gate \u2014 GSE337521 (BTKi + anti-CD20 + spatial MZL): peptide 0/3, AI infrastructure 1/3, longevity 0/3, low-cost/ease 3/3, translational fit 3/3 = 7/15; GSE262166 (Claudin-1 mAb in CCA): peptide 1/3, AI infrastructure 1/3, longevity 0/3, low-cost/ease 3/3, translational fit 3/3 = 8/15; GSE312779 (DMD cardiomyopathy + steroid multiomics): peptide 0/3, AI infrastructure 1/3, longevity 3/3, low-cost/ease 3/3, translational fit 2/3 = 9/15. Combined 24/45. All three are first-time primary features today and absent from id:43-id:48. Next action: reproduce BTKi-resistance + CD20-cold-tumor calls on GSE337521 spatial samples; benchmark Claudin-1 expression across CCA molecular subtypes from GSE262166; intersect GSE312779 steroid-response signatures with GSE330697 (yesterday's id:47) exercise-response signatures to define a conserved muscle-aging axis before any chemistry or therapeutic claim. --- ## 💼 Next Steps - **[View BTKi + anti-CD20 + spatial MZL dataset](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337521)** - **[View Claudin-1 mAb + CCA dataset](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE262166)** - **[View DMD cardiomyopathy + steroid multiomics dataset](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312779)** - **[Request integrated refractory-cancer + anti-aging brief](https://brownbio.tech/multiomics#brief)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-07-21 06:08 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-07-21
PubMed/GEO scan · research-watcher · 06:00 KST